[{"id":"f2c492b8-d008-47fb-bfe0-8880113c29ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113289","created_at":"2023-11-02T15:12:40.366Z","updated_at":"2025-02-25T15:21:01.496Z","phase":"Phase 1/2","brief_title":"A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT06113289","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NF1 • PTPN11","pipe":"","alterations":" ","tags":["KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-12"},{"id":"59fe4335-1fcc-4358-b0b0-f40604168b4d","acronym":"HERKULES-3","url":"https://clinicaltrials.gov/study/NCT05039177","created_at":"2021-09-09T13:53:09.950Z","updated_at":"2025-02-25T15:19:15.517Z","phase":"Phase 1/2","brief_title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","source_id_and_acronym":"NCT05039177 - HERKULES-3","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • NRAS mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Ibrance (palbociclib) • Braftovi (encorafenib) • ERAS-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-11"},{"id":"2869d37d-694e-4b7a-9927-ad103fab9714","acronym":"EAY131-Z1L","url":"https://clinicaltrials.gov/study/NCT06400225","created_at":"2024-05-06T20:27:17.855Z","updated_at":"2025-02-25T16:34:08.772Z","phase":"Phase 2","brief_title":"Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)","source_id_and_acronym":"NCT06400225 - EAY131-Z1L","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-07"},{"id":"4c83f544-8bf0-4858-908c-410296c3f0b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804227","created_at":"2023-04-07T13:03:03.068Z","updated_at":"2024-07-02T16:34:59.598Z","phase":"Phase 1","brief_title":"Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults","source_id_and_acronym":"NCT05804227","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 09/22/2025","primary_completion_date":" 09/22/2025","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2024-06-03"},{"id":"9d379a3d-e6e5-4272-912a-3b641b499609","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616183","created_at":"2021-01-19T20:33:33.700Z","updated_at":"2024-07-02T16:35:00.055Z","phase":"Phase 1/2","brief_title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04616183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • MAP2K1","pipe":"","alterations":" ","tags":["KRAS • BRAF • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"cb3171df-fc1d-4edc-a68b-8e666a6750ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04391595","created_at":"2021-01-18T21:11:39.818Z","updated_at":"2024-07-02T16:35:12.669Z","phase":"Phase 1","brief_title":"LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients","source_id_and_acronym":"NCT04391595","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-27"},{"id":"ce7736e3-4863-45a5-b48c-d8ac19bf73bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05985954","created_at":"2023-08-14T15:09:48.856Z","updated_at":"2024-07-02T16:35:13.039Z","phase":"Phase 1","brief_title":"Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy","source_id_and_acronym":"NCT05985954","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/18/2024","start_date":" 01/18/2024","primary_txt":" Primary completion: 03/28/2026","primary_completion_date":" 03/28/2026","study_txt":" Completion: 03/28/2028","study_completion_date":" 03/28/2028","last_update_posted":"2024-03-25"},{"id":"0ff46655-3196-4e55-a296-9ffdaa5cc8b1","acronym":"UTAH","url":"https://clinicaltrials.gov/study/NCT04145297","created_at":"2021-01-18T20:14:00.569Z","updated_at":"2024-07-02T16:35:13.869Z","phase":"Phase 1","brief_title":"Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas","source_id_and_acronym":"NCT04145297 - UTAH","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • HRAS • RAS","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 08/18/2022","study_completion_date":" 08/18/2022","last_update_posted":"2024-03-20"},{"id":"a03225ff-24b0-4deb-bd39-a4f4a7489157","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221320","created_at":"2022-02-05T18:29:02.167Z","updated_at":"2024-07-02T16:35:19.608Z","phase":"Phase 2","brief_title":"Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies","source_id_and_acronym":"NCT05221320","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3","pipe":" | ","alterations":" MSI-H/dMMR","tags":["KRAS • BRAF • MSI • HRAS • MAP2K1 • RAS • MAPK1 • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 05/26/2022","start_date":" 05/26/2022","primary_txt":" Primary completion: 12/06/2024","primary_completion_date":" 12/06/2024","study_txt":" Completion: 03/19/2025","study_completion_date":" 03/19/2025","last_update_posted":"2024-02-13"},{"id":"92b543b8-0666-45b8-8525-786af02d2693","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418167","created_at":"2021-01-18T21:17:40.725Z","updated_at":"2024-07-02T16:35:20.996Z","phase":"Phase 1","brief_title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","source_id_and_acronym":"NCT04418167","lead_sponsor":"JS InnoPharm, LLC","biomarkers":" MAP2K1 • NF1 • RASA1","pipe":" | ","alterations":" BRAF V600E • BRAF V600K","tags":["MAP2K1 • NF1 • RASA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tafinlar (dabrafenib) • JSI-1187"],"overall_status":"Suspended","enrollment":" Enrollment 71","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/17/2024","study_completion_date":" 12/17/2024","last_update_posted":"2024-02-02"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"},{"id":"e7db6484-cb3f-4fec-baf5-e9188f814ac7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03745989","created_at":"2021-07-05T17:18:24.986Z","updated_at":"2024-07-02T16:35:41.979Z","phase":"Phase 1b","brief_title":"Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)","source_id_and_acronym":"NCT03745989","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib) • MK-8353"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/22/2019","start_date":" 02/22/2019","primary_txt":" Primary completion: 03/19/2021","primary_completion_date":" 03/19/2021","study_txt":" Completion: 03/19/2021","study_completion_date":" 03/19/2021","last_update_posted":"2023-07-27"},{"id":"dde5d7d2-1dad-4eff-ab54-2b67e2cc553a","acronym":"HERKULES-2","url":"https://clinicaltrials.gov/study/NCT04959981","created_at":"2021-12-13T15:11:31.264Z","updated_at":"2024-07-02T16:35:42.103Z","phase":"Phase 1b","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC","source_id_and_acronym":"NCT04959981 - HERKULES-2","lead_sponsor":"Erasca, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Lumakras (sotorasib) • ERAS-007 • ERAS-601"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/02/2021","start_date":" 09/02/2021","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/27/2023","study_completion_date":" 04/27/2023","last_update_posted":"2023-07-25"},{"id":"45305998-fa64-4d07-b93d-837bfa07fbb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02972034","created_at":"2021-01-18T14:36:36.141Z","updated_at":"2024-07-02T16:35:54.334Z","phase":"Phase 1","brief_title":"Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)","source_id_and_acronym":"NCT02972034","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • MSI","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-8353"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 01/13/2017","start_date":" 01/13/2017","primary_txt":" Primary completion: 12/02/2022","primary_completion_date":" 12/02/2022","study_txt":" Completion: 12/02/2022","study_completion_date":" 12/02/2022","last_update_posted":"2023-03-02"},{"id":"4e483bfe-5e97-41db-b857-047a1c9033b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02857270","created_at":"2021-01-18T14:01:31.198Z","updated_at":"2024-07-02T16:36:00.102Z","phase":"Phase 1","brief_title":"A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer","source_id_and_acronym":"NCT02857270","lead_sponsor":"Eli Lilly and Company","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 210","initiation":"Initiation: 09/29/2016","start_date":" 09/29/2016","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2022-11-22"},{"id":"330ac409-c653-4ffe-b5ad-e37d750b01db","acronym":"HERKULES-4","url":"https://clinicaltrials.gov/study/NCT05279859","created_at":"2022-03-15T18:52:50.830Z","updated_at":"2024-07-02T16:36:08.894Z","phase":"Phase 1b/2","brief_title":"A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05279859 - HERKULES-4","lead_sponsor":"Erasca, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xospata (gilteritinib) • ERAS-007 • ERAS-601"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-06-15"},{"id":"0b0004ce-6bfe-4d8e-982a-5d46b487e30e","acronym":"SHERPA","url":"https://clinicaltrials.gov/study/NCT04916236","created_at":"2021-06-07T15:53:34.728Z","updated_at":"2024-07-02T16:36:09.403Z","phase":"Phase 1","brief_title":"Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers","source_id_and_acronym":"NCT04916236 - SHERPA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EGFR • KRAS • PIK3CA • MET • PTEN • HRAS","pipe":"","alterations":" ","tags":["EGFR • KRAS • PIK3CA • MET • PTEN • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-06-03"},{"id":"88762fb2-bc78-461a-9433-192ed0a1e084","acronym":"","url":"https://clinicaltrials.gov/study/NCT03415126","created_at":"2021-01-18T16:50:58.681Z","updated_at":"2024-07-02T16:36:43.443Z","phase":"Phase 1","brief_title":"A Study of ASN007 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03415126","lead_sponsor":"Asana BioSciences","biomarkers":" KRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation","tags":["KRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERAS-007"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2020-07-09"},{"id":"36c39bba-f90e-4ec9-b285-fc30dd8481e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01781429","created_at":"2021-01-17T17:38:51.630Z","updated_at":"2024-07-02T16:36:47.933Z","phase":"Phase 1/2","brief_title":"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies","source_id_and_acronym":"NCT01781429","lead_sponsor":"BioMed Valley Discoveries, Inc","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • ER mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • ER mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2020-03-20"}]